TREVENA,INC. (NASDAQ:TRVN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item 5.02Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.

On December15, 2016, the Board of Directors of Trevena,Inc. (the
Company) adopted the Trevena,Inc. Inducement Plan (the Inducement
Plan), to be effective on January1, 2017, to which the Company
reserved 500,000 shares of the Companys common stock for issuance
under the Inducement Plan. The only persons eligible to receive
grants of Awards (as defined below) under the Inducement Plan are
individuals who satisfy the standards for inducement grants under
Nasdaq Marketplace Rule5635(c)(4)and the related guidance under
Nasdaq IM 5635-1, including individuals who were not previously
an employee or director of the Company or are following a bona
fide period of non-employment, in each case as an inducement
material to such individuals agreement to enter into employment
with the Company. An Award is any right to receive the Companys
common stock to the Inducement Plan, consisting of nonstatutory
stock options and restricted stock unit awards. On December15,
2016, the Companys Board of Directors also adopted forms of
agreements for use with the Inducement Plan.

The description above of the terms of the Inducement Plan is not
complete, and reference is made to the Inducement Plan filed as
Exhibit10.1 hereto for a full description of the terms of the
Inducement Plan. The forms of notices and agreements for use with
the Inducement Plan are attached as Exhibits 10.2 and 10.3
hereto.

Item9.01. Financial Statements and
Exhibits.

(d) Exhibits

About TREVENA, INC. (NASDAQ:TRVN)

Trevena Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors (GPCRs). Using its product platform, the Company has identified and advanced three differentiated product candidates: Oliceridine (TRV130), TRV027 and TRV250. Its TRV130 is a Mu-receptor G protein Pathway Selective (Mu-GPS) modulator that activates G protein. Its TRV250 is a small molecule G protein biased ligand of the d-opioid receptor in preclinical development. Its TRV734 is a small molecule Mu-GPS that it has discovered and has developed through Phase I as a first-line, orally administered compound for the treatment of moderate to severe acute and chronic pain. Its TRV027 is a peptide b-arrestin biased ligand that targets the angiotensin II type 1 receptor (AT1R). In addition to these three product candidates, the Company has identified and has completed the Phase I program for TRV734.

TREVENA, INC. (NASDAQ:TRVN) Recent Trading Information

TREVENA, INC. (NASDAQ:TRVN) closed its last trading session down -0.08 at 5.82 with 307,908 shares trading hands.